VCP and Parkinson disease: p97 is considered a drug target in certain cancers and clinical trials are under way (Anderson et al, 2015; Skrott et al, 2017; Roux et al, 2021), whereas missense mutations in p97 cause a dominantly inherited multisystem proteinopathy‐1 (MSP‐1) featuring inclusion body myopathy, Paget's disease of bone, amyotrophic lateral sclerosis, frontotemporal dementia, and Parkinsonism (Kimonis et al, 2008).